首页> 外国专利> RECOMBINANT PLASMID pET-15b_T1_RL DNA PROVIDING SYNTHESIS OF RECOMBINANT FUSION PROTEIN CONSISTING OF TUMOR-SPECIFIC PEPTIDES AND ANTITUMOR PEPTIDE RL2, AND RECOMBINANT FUSION PROTEIN POSSESSING CYTOTOXIC ACTIVITY AGAINST CANCER CELLS AND TARGETED PROPERTIES AGAINST TUMOR TISSUE

RECOMBINANT PLASMID pET-15b_T1_RL DNA PROVIDING SYNTHESIS OF RECOMBINANT FUSION PROTEIN CONSISTING OF TUMOR-SPECIFIC PEPTIDES AND ANTITUMOR PEPTIDE RL2, AND RECOMBINANT FUSION PROTEIN POSSESSING CYTOTOXIC ACTIVITY AGAINST CANCER CELLS AND TARGETED PROPERTIES AGAINST TUMOR TISSUE

机译:重组质粒pET-15b_T1_RL DNA可合成包含肿瘤特异性肽和抗原肽RL2的重组融合蛋白,重组融合蛋白具有抵抗癌变和抗癌的能力。

摘要

FIELD: biotechnology.;SUBSTANCE: pET-15b_T1_RL plasmid DNA is constructed which provides synthesis of recombinant fusion protein consisting of a tumor-specific peptide and an antitumor peptide RL2. The recombinant fusion protein isolated from Escherichia coli cells transformed with pET-15b_T1_RL plasmid, has a molecular weight of 15.7 kDa, consists of methionine residue, tumor specific peptide GLHTSATNLYLH, glycine GGGS spacer, and a recombinant lactaptin RL2 analogue.;EFFECT: production of a protein providing cytotoxic activity against cancer cells in culture and targeted properties for tumor tissue.;2 cl, 6 dwg, 5 ex
机译:领域:生物技术;实质:pET-15b_T1_RL质粒DNA的构建可提供由肿瘤特异性肽和抗肿瘤肽RL2组成的重组融合蛋白的合成。从pET-15b_T1_RL质粒转化的大肠杆菌细胞中分离得到的重组融合蛋白,分子量为15.7 kDa,由蛋氨酸残基,肿瘤特异性肽GLHTSATNLYLH,甘氨酸GGGS间隔子和重组乳杆菌蛋白酶RL2类似物组成。一种蛋白质,对培养的癌细胞具有细胞毒活性,并具有针对肿瘤组织的靶向特性。; 2 cl,6 dwg,5 ex

著录项

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号